$0.98
1.00% today
Nasdaq, Apr 04, 09:47 pm CET
ISIN
US81362J1007
Symbol
VANI

Second Sight Medical Products, Inc. Stock price

$0.99
-0.09 8.33% 1M
-0.13 11.61% 6M
-0.17 14.66% YTD
-1.05 51.35% 1Y
-3.51 78.00% 3Y
-1.53 60.71% 5Y
-290.37 99.66% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.02 1.98%
ISIN
US81362J1007
Symbol
VANI
Sector

Key metrics

Market capitalization $58.65m
Enterprise Value $59.85m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.33
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-24.68m
Free Cash Flow (TTM) Free Cash Flow $-21.34m
Cash position $18.35m
EPS (TTM) EPS $-0.43
P/E forward negative
Short interest 0.83%
Show more

Is Second Sight Medical Products, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Second Sight Medical Products, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Second Sight Medical Products, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Second Sight Medical Products, Inc. forecast:

Buy
100%

Financial data from Second Sight Medical Products, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.40 0.40
11% 11%
-
-0.40 -0.40
11% 11%
-
- Selling and Administrative Expenses 8.14 8.14
12% 12%
-
- Research and Development Expense 16 16
7% 7%
-
-24 -24
9% 9%
-
- Depreciation and Amortization 0.40 0.40
11% 11%
-
EBIT (Operating Income) EBIT -25 -25
8% 8%
-
Net Profit -23 -23
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Second Sight Medical Products, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Second Sight Medical Products, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
Successful initial administration and full enrollment in first-in-human LIBERATE-1 ™ study of NPM-115 (exenatide implant) in obese and overweight subjects with top-line data expected in mid-2025
Neutral
GlobeNewsWire
8 days ago
Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company's once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management ALAMEDA, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical...
Neutral
GlobeNewsWire
9 days ago
NanoPortal™  technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant)
More Second Sight Medical Products, Inc. News

Company Profile

Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

Head office United States
CEO Adam Mendelsohn
Employees 42
Founded 2003
Website www.vivani.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today